Engineered immune cells take on pancreatic cancer in first human trial

NCT ID NCT07153289

Not yet recruiting Disease control Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a new treatment called CD318-CAR-T cells for people with advanced pancreatic cancer that has worsened after standard therapy. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study aims to check if the treatment is safe and feasible, and to get an early look at whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD318-targeted CAR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could point toward a new treatment option for advanced pancreatic cancer, a disease with very few effective therapies.
What could go wrong: This is a very early, first-in-human trial with only 38 participants. CAR-T cell therapy can cause severe side effects like cytokine release syndrome, and it is unknown if it will work against solid tumors like pancreatic cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, PANCREATIC DUCTAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, PANCREATIC DUCTAL PANCREATIC NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.